Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia.

Autor: Abernathy KM; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, USA., Perciavalle MA; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, USA., Gatwood KS; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, USA., Chen H; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, USA., Zakhari MM; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, USA., Byrne M; Department of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, USA.

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Sep; Vol. 29 (6), pp. 1326-1333. Date of Electronic Publication: 2022 Aug 09.

Evaluation of healthcare-associated infection rates in patients with hematologic malignancies and stem cell transplantation during the coronavirus disease 2019 (COVID-19) pandemic.

Autor: Bobbitt LJ; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee., Satyanarayana G; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Van Metre Baum L; Division of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut., Nebhan CA; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Kassim AA; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Gatwood KS; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee.

Publikováno v: Antimicrobial stewardship & healthcare epidemiology : ASHE [Antimicrob Steward Healthc Epidemiol] 2022 Jan 17; Vol. 2 (1), pp. e11. Date of Electronic Publication: 2022 Jan 17 (Print Publication: 2022).

New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Autor: Mangan BL; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Patel D; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Chen H; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Gatwood KS; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Byrne MT; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Sengsayadeth S; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Goodman S; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Kassim AA; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Jagasia M; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Chinratanalab W; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Culos KA; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Engelhardt BG; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Publikováno v: EJHaem [EJHaem] 2020 Nov; Vol. 1 (2), pp. 576-580. Date of Electronic Publication: 2020 Sep 23.

Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study.

Autor: Baskett J; Department of Pharmacy, Duke University Hospital, Durham, NC, USA., Culos KA; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Satyanarayana G; Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, TN, USA., Patel D; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Engelhardt B; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Savani B; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Jagasia M; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Kassim AA; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Gatwood KS; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA. Katie.s.gatwood@vumc.org.; Division of Pharmaceutical Sciences, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 1301 Medical Center Drive, Nashville, TN, 37232, USA. Katie.s.gatwood@vumc.org.

Publikováno v: Annals of hematology [Ann Hematol] 2020 May; Vol. 99 (5), pp. 1137-1139. Date of Electronic Publication: 2020 Mar 06.

Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.

Autor: Gatwood KS; Vanderbilt University Medical Center, Nashville, TN, USA. katie.s.gatwood@vumc.org., Labopin M; EBMT Paris Study Office/CEREST-TC, Paris, France., Savani BN; Vanderbilt University Medical Center, Nashville, TN, USA., Finke J; University of Freiburg Department of Medicine-Hematology, Oncology, Freiburg, Germany., Socie G; Department of Hematology-BMT, Hospital St. Louis, Paris, France., Beelen D; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany., Yakoub-Agha I; Hôpital HURIEZ, UAM allo-CSH, CHRU, Lille, France., Chevallier P; Dept. D'Hématologie, CHU Nantes, Nantes, France., Ganser A; Department of Haematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str.1, Hannover, Germany., Blaise D; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France., Milpied N; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France., Bruno L; Techniciens d'Etude Clinique suivi de patients greffes, Nouvel Hopital Civil, Strasbourg, France., Mailhol A; EBMT Paris Study Office/CEREST-TC, Paris, France., Mohty M; Department of Hematology, Hopital Saint Antoine, Paris, France., Nagler A; Department of Hematology, Hopital Saint Antoine, Paris, France.; Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2020 Jan; Vol. 55 (1), pp. 224-232. Date of Electronic Publication: 2019 Sep 16.